Kunal Dansingani, MD
Retina Specialist · Hauppauge, NYNPI 1568825628
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Biogen at 58.5% of the total. Reporting peaked in 2021 at $2,000 and has fallen 71.9% since, to $562 in 2025.
Across 19 payments — averaging $180.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$2K
- Alcon$832
- Regeneron Healthcare Solutions, Inc.$225
- Tarsus Pharmaceuticals, Inc.$118
- Mallinckrodt Hospital Products Inc.$74
- Apellis Pharmaceuticals, Inc.$73
- plus $99 from 3 others
Across 9 payments — averaging $9119.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$82K
What the payments were for
- Consulting fees$2,00058%
- Travel & lodging$45213%
- Food & beverage$96928%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 1 | $2,000 |
| Alcon | 3 | $832 |
| Regeneron Healthcare Solutions, Inc. | 4 | $225 |
| Tarsus Pharmaceuticals, Inc. | 1 | $118 |
| Mallinckrodt Hospital Products Inc. | 2 | $74 |
| Apellis Pharmaceuticals, Inc. | 3 | $73 |
| Genentech USA, Inc. | 2 | $45 |
| Alimera Sciences, Inc. | 2 | $27 |
| Astellas Pharma US Inc | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,421 in reported general payments places this provider in the 60th percentile of 99 retina specialist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 35 | $1,531 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 25 | $541 |
| Ketorolac Tromethamine | 34 | $463 |
| Latanoprost | 17 | $142 |
| Brimonidine Tartrate | 12 | $118 |
| Timolol Maleate | 13 | $49 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Hauppauge
- Albert LiHauppauge$4K
- Paul HahnNanuet$238K
- Deepika MalikWoodbury$221K
- Szilard KissNew York$195K
- Ferhina AliValhalla$176K
- Donald D'amicoNew York$109K
- Matthew WitmerRochester$62K
- Avnish DeobhaktaBrooklyn$46K
- Edward HallRochester$38K
- Philip NilesWilliamsville$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.